Key result
Antithrombotic therapy does not significantly increase bleeding risk during oral implant surgery.
Why the study?
The risk of postoperative bleeding during implant placement surgery in patients taking antithrombotics was uncertain.
Does antithrombotic treatment increase the risk of postoperative bleeding in patients undergoing oral surgery for implant placement?
Systematic Review
Does antithrombotic treatment increase the risk of postoperative bleeding in patients undergoing oral surgery for implant placement?
Continuing antithrombotic therapy during dental implant surgery does not significantly increase the risk of bleeding, supporting the practice of not discontinuing these medications.
Answers are grounded in this paper and cite their sources.
Supports continuing antithrombotics without interruption during implant surgery; reinforces current practice while warranting larger trials for precision.
The objective of this systematic review is to assess the risk of postoperative bleeding in oral surgery for implant placement in individuals taking antithrombotics (i.e., anticoagulants and/or antiplatelet agents). A literature search was performed in PubMed (MEDLINE), Web of Science, Scopus, and EMBASE databases for articles published until August 2020, with no date restriction, and manually completed. We included prospective clinical studies that provided information regarding the presence of an experimental group (i.e., implant placement), a control group (patients not under treatment with antithrombotics), and a well-established protocol for evaluating bleeding. Meta-analysis determined the risk of bleeding during the placement of implants in antithrombotic-treated patients. Of the 756 potentially eligible articles, 5 were included in the analysis with 4 ranked as high and 1 as medium quality. Antithrombotic treatment comprised the following drug classes: (1) anticoagulants: vitamin K antagonists, (2) nonvitamin K antagonist oral anticoagulants, (3) low-molecular-weight heparin, and (4) antiplatelet agents (not specified). The results suggest that the risk of bleeding is not substantially higher in antithrombotic-treated patients (odds ratio = 2.19; 95% confidence interval: 0.88–5.44, p = 0.09) compared with nontreated patients. This systematic review suggests that the absolute risk is low and there is no need to discontinue or alter the dose of the antithrombotic treatment for implant placement surgery.
No takes yet. Share an insight, caveat, or question.
Miziara et al. (2021) conducted a systematic review in oral surgery for implant placement. Antithrombotics (anticoagulants and/or antiplatelet agents) vs. Patients not under treatment with antithrombotics was evaluated on postoperative bleeding (OR 2.19, 95% CI 0.88-5.44, p=0.09). Antithrombotic treatment during oral implant surgery was not associated with a higher risk of bleeding compared with no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: